Menu
Back to Journals » OncoTargets and Therapy » Volume 6
Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer
Authors Sun W , Ai T, Gao Y, Zhang Y, Cui J, Song L
Received 24 June 2013
Accepted for publication 29 July 2013
Published 18 September 2013 Volume 2013:6 Pages 1315—1323
DOI https://doi.org/10.2147/OTT.S50428
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Wenze Sun,1 Ting Ai,2 Ying Gao,1 Yingbing Zhang,1 Jie Cui,1 Liping Song1
1Department of Radiation Oncology, 2Department of Neonatology, First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an, People's Republic of China
Background: MET is involved in the progression of several types of human cancers, while phospho-BAD(Ser-136) is a key molecule in apoptosis and might be regulated by MET. The aim of this study was to investigate the correlation between altered expression of MET and phospho-BAD in non-small cell lung cancer (NSCLC) and their association with clinicopathologic parameters and overall survival.
Methods: MET and phospho-BAD(Ser-136) proteins were evaluated by immunohistochemical analysis in 183 paraffin-embedded specimens and were also assessed by Western blotting analysis in 12 frozen tumor tissue samples, which were representative examples of immunohistochemical staining.
Results: Positive expression of MET and phospho-BAD(Ser-136) occurred in 67.2% and 49.2% of the 183 cases of NSCLC, respectively. However, neither MET expression nor phospho-BAD(Ser-136) expression was associated with any clinicopathologic parameter. A significant correlation was found between MET and phospho-BAD(Ser-136) expression levels evaluated by immunohistochemistry (r = 0.268, P < 0.001). Overexpression of MET was significantly associated with shortened overall survival in univariate analysis (P < 0.001). Moreover, patients with a MET+/phospho-BAD(Ser-136)+ phenotype had a poorer prognosis than others (P < 0.001). Multivariate Cox proportional hazard analysis confirmed that MET expression is a prognostic factor for NSCLC.
Conclusion: MET expression might be correlated with phospho-BAD(Ser-136) expression, and may be an adverse predictor for NSCLC. Activation of the MET/phospho-BAD(Ser-136) signaling pathway might play a role in the development and progression of NSCLC.
Keywords: MET, phospho-BAD, prognosis, non-small cell lung cancer
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.